Core Insights - Integra LifeSciences Holdings Corporation (IART) reported adjusted earnings per share (EPS) of 83 cents for Q4 2025, exceeding the Zacks Consensus Estimate by 4.7%, but down 14.4% year over year [1][2] - Total revenues for Q4 2025 were $434.9 million, a decrease of 1.7% year over year, but slightly above the Zacks Consensus Estimate by 0.1% [3] - The company provided guidance for 2026, expecting revenues between $1.66 billion and $1.70 billion, and adjusted EPS between $2.30 and $2.40 [11][12] Financial Performance - GAAP loss per share was 2 cents in Q4 2025, compared to earnings of 25 cents in the same period last year [2] - Full-year 2025 adjusted EPS was $2.23, down 12.9% year over year [2] - Gross profit for Q4 2025 totaled $220.9 million, down 11.3% year over year, with a gross margin of 50.8%, a contraction of 549 basis points [7][9] Revenue Breakdown - Revenues in the Codman Specialty Surgical segment rose 2.7% year over year to $323.3 million, with Neurosurgery sales growing 1.4% [4] - Tissue Technologies' revenues fell 12.8% year over year to $111.6 million, with Wound Reconstruction sales declining 21.4% on an organic basis [5] - Private Label sales grew 20.1% due to improved partner orders [6] Operational Insights - The adjusted operating profit was $26.8 million, down 31.9% year over year, with an adjusted operating margin of 6.2%, a contraction of 272 basis points [9] - The company ended Q4 2025 with approximately $235 million in cash and cash equivalents, down from $246.4 million a year ago [10] - Cumulative net cash provided by operating activities was $50.4 million, compared to $129.4 million a year ago [10] Future Guidance - For Q1 2026, reported revenues are expected to be between $375 million and $390 million, with adjusted EPS anticipated in the range of 37 to 45 cents [12] - The Zacks Consensus Estimate for Q1 2026 revenues is pegged at $395 million, and for adjusted EPS at 43 cents [12]

Core Insights - The company has made significant improvements in quality and manufacturing, establishing mechanisms for disciplined execution and accountability, which are translating into better operational performance [1][3][11] - The company reported fourth-quarter revenue of $435 million and adjusted earnings per share of $0.83, both exceeding guidance expectations, indicating strong operational and strategic progress [3][12] - The company is focused on a dual strategy of enhancing quality and supply chain reliability while also driving growth and innovation, with specific initiatives planned for 2026 [6][7][27] Financial Performance - Full year 2025 revenue was $1.635 billion, reflecting a 1.5% growth on a reported basis, with a 0.7% organic decline due to quality remediation and supply constraints [12][14] - The fourth quarter saw a revenue decrease of 1.7% on a reported basis and a 2.5% organic decline, attributed to strong prior year comparisons [14][15] - Full year gross margin was 61.9%, down 260 basis points year-over-year, influenced by tariffs and supply pressures [13][15] Strategic Initiatives - The company launched a supply chain control tower for better visibility into operational metrics and performance across its global network [1] - A new operating model has been implemented to reduce complexity and improve efficiency, alignment, and accountability [5][6] - The company is focused on four strategic imperatives for 2026: delivering best-in-class quality, driving supply chain reliability, accelerating growth, and igniting innovation [6][7] Product Development and Market Position - The company relaunched PriMatrix and Durepair ahead of schedule, receiving positive customer feedback, and is on track to bring SurgiMend back to market in Q4 2026 [8][42] - The company anticipates strong demand for its products, particularly in the outpatient wound care market, following recent reimbursement changes [9][41] - The company is strengthening its R&D processes and has appointed a new Chief Technology Officer to enhance innovation efforts [10] Market Outlook - The company expects first quarter 2026 revenues to range from $375 million to $390 million, reflecting a slight decline due to order timing and product remediation [21][22] - For the full year 2026, revenue is projected to be between $1.66 billion and $1.7 billion, indicating modest growth expectations [22] - The company is optimistic about its long-term growth prospects, supported by strong positions in attractive end markets and ongoing operational improvements [11][27]

Revenue Segments - Integra LifeSciences generates approximately 70% of its total revenue from the Codman Specialty Surgical (CSS) segment, which includes technologies for neurosurgery and ENT [17]. - The CSS segment includes leading products such as the CUSA® platform and CereLink® ICP Monitor, which are critical for neurosurgical procedures [20]. - The Tissue Technologies segment accounts for about 30% of overall revenue, focusing on wound reconstruction and care [17]. Global Expansion and Manufacturing - Integra has expanded its global presence, particularly in Southeast Asia, India, South Korea, and Brazil, enhancing its manufacturing capabilities in Suzhou, China [32]. - The company is investing in capacity expansion, including relocating manufacturing from Boston to Braintree, Massachusetts, and enhancing processes in Plainsboro, New Jersey [46]. - The company is consolidating its manufacturing facilities, including plans to operationalize its Braintree facility by the first half of 2026, which may involve unforeseen costs and delays [178]. Research and Development - The company has a robust R&D strategy aimed at introducing new products and improving existing technologies, with a focus on unmet surgical needs [34]. - Integra's CerebroFlo® EVD catheter has shown an average of 99% less thrombus accumulation compared to a leading competitor, indicating significant advancements in technology [38]. - In 2024, Integra acquired the rights for Durepair Dural Regeneration Matrix, which was launched for commercial sale in the U.S. in October 2025 [44]. Regulatory Compliance - The company is subject to extensive FDA regulations, which govern the development, testing, and marketing of medical devices, impacting the time and cost of bringing new products to market [62][64]. - The regulatory process for new medical devices can be onerous, requiring premarket authorization and potentially extensive clinical testing [65][66]. - The company must demonstrate substantial equivalence to a predicate device for FDA clearance, which can significantly impact the device development timeline [69]. Market Dynamics and Competition - The company faces significant competition from major players like Medtronic and Stryker, as well as smaller specialized companies, emphasizing the importance of product efficacy and cost-effectiveness [56][58]. - Revenue patterns show that the fourth quarter typically has the highest sales due to hospitals increasing purchases at the end of their budget cycles [54]. - Increased competition in the medical device industry may hinder the company's ability to maintain market acceptance and profitability, as competitors may have greater resources [147]. Financial Performance and Risks - The company recognized an aggregate charge of $511.4 million in goodwill impairment expense during Q2 2025 due to a quantitative assessment of its reporting units, influenced by tariff changes and economic uncertainty [165]. - The company's total consolidated external debt was approximately $1.9 billion as of December 31, 2025 [210]. - The company’s debt service obligations may impede growth by requiring a portion of operating cash flow to pay interest and principal [211]. Employee and Workplace Initiatives - The company has eight Integra-sponsored Business Resource Groups (BRGs) aimed at providing career development and leadership opportunities [129]. - Employee health and wellbeing programs include comprehensive health insurance, disability coverage, and wellness initiatives to promote healthy behaviors [137]. - The company emphasizes a pay-for-performance compensation philosophy, regularly conducting pay equity analyses to ensure fair compensation practices [131]. Environmental and Social Governance - The company published its annual environmental, social, and governance (ESG) report in Q3 2025, highlighting its commitment to sustainability initiatives [126]. - The company is subject to environmental regulations that may impose significant compliance costs and risks related to hazardous materials [202]. - The company is exposed to risks from environmental, social, and corporate governance issues, which could increase operating costs and affect reputation [204]. Healthcare Policy and Reimbursement - Market acceptance of medical products is heavily influenced by reimbursement practices from government programs and private insurers, with increasing demands for clinical evidence [100]. - Legislative changes, such as the Budget Control Act of 2011, have resulted in a 2% reduction in Medicare payments to providers, effective through 2033 [104]. - The adoption of the OBBBA is projected to decrease federal healthcare spending by approximately $1.0 trillion, impacting the company's operations [195]. Supply Chain and Operational Challenges - The company relies on independent suppliers for key components and materials, and any disruption in their operations could lead to inventory shortages and impact product manufacturing [169]. - Supply constraints have increased production costs for certain products, which the company may not be able to pass on to customers, impacting future profitability [180]. - The company is exposed to geopolitical uncertainties and supply chain disruptions that could negatively impact its financial condition and operational results [143]. Compliance and Legal Risks - The company faces significant compliance risks in international operations, which may lead to government investigations and substantial fines, negatively impacting its financial condition and cash flows [158]. - The FDA's position prohibits device manufacturers from promoting products for unapproved uses, which could expose the company to significant penalties [185]. - The company is subject to the provisions of the U.S. FCPA and other international anti-bribery laws, which could disrupt operations if violated [191].

Core Insights - Integra LifeSciences reported revenue of $434.93 million for the quarter ended December 2025, reflecting a decrease of 1.7% year-over-year, with EPS at $0.83 compared to $0.97 in the same quarter last year [1] - The revenue exceeded the Zacks Consensus Estimate of $434.35 million by 0.13%, while the EPS surpassed the consensus estimate of $0.79 by 4.73% [1] Revenue Performance - Organic revenue growth was reported at -2.5%, better than the three-analyst average estimate of -3.5% [4] - Codman Specialty Surgical revenue totaled $323.31 million, exceeding the average estimate of $306.21 million by two analysts, representing a year-over-year increase of 2.8% [4] - Tissue Technologies - Private Label revenue was $31.64 million, surpassing the average estimate of $24.41 million, marking a year-over-year growth of 19.6% [4] - Tissue Technologies - Wound Reconstruction and Care revenue was $79.98 million, below the average estimate of $99.43 million, indicating a year-over-year decline of 21.2% [4] - Total revenue for Tissue Technologies was $111.62 million, falling short of the average estimate of $123.85 million, reflecting a year-over-year decrease of 12.8% [4] Stock Performance - Shares of Integra have returned +6.5% over the past month, outperforming the Zacks S&P 500 composite, which saw a change of +0.6% [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Financial Data and Key Metrics Changes - Full year 2025 revenue was $1.635 billion, representing 1.5% growth on a reported basis and a 0.7% organic decline [15] - Fourth quarter revenues were $435 million, reflecting a decrease of 1.7% on a reported basis and an organic decline of 2.5% [17] - Full-year gross margin was 61.9%, down 260 basis points year-over-year, while fourth quarter gross margin was 61.7%, down 350 basis points from the prior year [16][18] - Adjusted earnings per share for the full year was $2.23, compared to $2.56 in 2024, and for the fourth quarter was $0.83 compared to $0.97 in the prior year [16][18] Business Line Data and Key Metrics Changes - In the global neurosurgery segment, organic growth was 1.4%, with double-digit growth in CereLink, MAYFIELD Capital, and AURORA [18] - Tissue Technologies revenues were $111.6 million, down 12.8% on both a reported and organic basis, with a 21.4% decline in the Wound Reconstruction franchise [19] - Private label sales in Tissue Technologies were up 20.1% year-over-year, driven by improved partner orders [19] Market Data and Key Metrics Changes - International markets contributed to high single-digit growth in the CSF business, led by double-digit performance in China and Canada [18] - Demand indicators across global markets remain strong, with expectations for continued growth in China [52] Company Strategy and Development Direction - The company is focused on four strategic imperatives: delivering best-in-class quality, driving supply chain reliability, accelerating growth, and igniting innovation [9][10] - A new operating model has been implemented to reduce complexity and improve efficiency, with a focus on disciplined execution and accountability [8] - The company plans to bring key products back to the market, including SurgiMend and DuraSorb, with a new manufacturing facility expected to be operational by mid-2026 [11][24] Management's Comments on Operating Environment and Future Outlook - Management acknowledged uncertainty around new tariffs and their potential impact on guidance for 2026 [4] - The company expects improved cash flow in 2026, with operating cash flow projected to exceed $200 million [31] - Management remains optimistic about long-term growth and value creation prospects, emphasizing the importance of quality management and supply reliability [14][26] Other Important Information - The company has welcomed six new leaders to its executive team, enhancing capabilities and supporting long-term growth [7] - The company is actively monitoring reimbursement changes and believes its pricing is well within the new reimbursement range [32] Q&A Session Summary Question: Free cash flow generation and improvement expectations for 2026 - Management explained that negative free cash flow in the quarter was driven by timing of collections and restructuring costs, but expects significant improvement in 2026 with operating cash flow projected to exceed $200 million [30][31] Question: Status of Tissue Technologies business and reimbursement changes - Management indicated that while there are reimbursement changes, they do not expect negative impacts on their business, as their pricing aligns with new reimbursement levels [32] Question: Growth assumptions for CSS and Tissue Technologies - Management provided insights on growth expectations, indicating low single-digit growth for CSS and low to mid single-digit growth for Tissue Technologies in 2026, driven by supply rather than demand [40] Question: Key milestones for Braintree and product relaunches - Management confirmed that Braintree is on track for operationalization by mid-2026, with ongoing process validations [45] Question: MediHoney remediation efforts - Management stated that revenues for MediHoney have not been accounted for in 2026 guidance, as remediation efforts continue [50] Question: International market dynamics and performance in China - Management noted strong performance in China and Canada, expecting continued growth contributions from these markets [52]

Financial Data and Key Metrics Changes - For the full year 2025, revenue was $1.635 billion, representing 1.5% growth on a reported basis and a 0.7% organic decline [15] - Fourth quarter revenues were $435 million, reflecting a decrease of 1.7% on a reported basis and an organic decline of 2.5% [17] - Full-year gross margin was 61.9%, down 260 basis points year-over-year, while adjusted EBITDA margin was 19.4%, down 60 basis points [16] - Adjusted EPS for the full year was $2.23, compared to $2.56 in 2024 [16] Business Line Data and Key Metrics Changes - Double-digit growth was achieved in Sterilink, Mayfield Capital, AURORA, DuraSorb, programmable valves, and fixed pressure valves for the full year 2025 [15] - Global neurosurgery delivered 1.4% organic growth, with strong performance in CereLink, MAYFIELD Capital, and AURORA [18] - Tissue Technologies revenues were $111.6 million, down 12.8% on both a reported and organic basis compared to the prior year [19] Market Data and Key Metrics Changes - International markets contributed to high single-digit growth in the CSF business, led by double-digit performance in China and Canada [18] - The capital business grew in the low double digits, benefiting from strong pipelines and disciplined commercial execution [18] Company Strategy and Development Direction - The company is focused on four strategic imperatives: delivering best-in-class quality, driving supply chain reliability, accelerating growth, and igniting innovation [10] - A new operating model has been implemented to reduce complexity and improve efficiency, alignment, and accountability [9] - The company aims to return key products to the market and recapture share while sharpening its approach to innovation and portfolio prioritization [26] Management's Comments on Operating Environment and Future Outlook - Management acknowledged uncertainty around new Section 122 tariffs but stated that 2026 guidance does not incorporate these changes [4] - The company expects improved cash flow in 2026, with operating cash flow projected to exceed $200 million [31] - Management remains confident in the long-term growth and value creation prospects, emphasizing the importance of quality management and supply reliability [14] Other Important Information - The company is actively monitoring the impact of recent tariff changes and has not accounted for any revenues from MediHoney in its 2026 guidance [50] - The Braintree manufacturing facility is expected to be operational by the end of June 2026, supporting the return of SurgiMend to the market in Q4 2026 [11] Q&A Session Summary Question: Free cash flow generation and improvement - Management explained that negative free cash flow was driven by timing of collections and restructuring costs, but expects significant improvement in 2026 [30] Question: Tissue Technologies business and CMS changes - Management noted that reimbursement changes are being monitored, and they do not expect negative impacts on their business due to pricing being within the new reimbursement range [32] Question: Growth assumptions for CSS and Tissue Tech - Management indicated that growth expectations for both CSS and Tissue Tech are below market due to supply constraints, not demand [40] Question: Status of MediHoney remediation efforts - Management confirmed that no revenues from MediHoney are accounted for in 2026 guidance, as remediation efforts continue [50] Question: Outlook for PriMatrix and DuraRepair - Management reported strong early reception for PriMatrix and DuraRepair following their relaunch, with plans for a measured ramp in 2026 [47]

Financial Data and Key Metrics Changes - For the full year 2025, revenue was $1.635 billion, representing 1.5% growth on a reported basis and a 0.7% organic decline [15] - Fourth quarter revenues were $435 million, reflecting a decrease of 1.7% on a reported basis and an organic decline of 2.5% [17] - Full-year gross margin was 61.9%, down 260 basis points year-over-year, while adjusted EBITDA margin was 19.4%, down 60 basis points [16] - Adjusted EPS for the full year was $2.23, compared to $2.56 in 2024 [16] Business Line Data and Key Metrics Changes - In the global neurosurgery segment, organic growth was 1.4%, with double-digit growth in CereLink, MAYFIELD Capital, and AURORA [18] - Tissue Technologies revenues were $111.6 million, down 12.8% on both a reported and organic basis, with a 21.4% decline in the Wound Reconstruction franchise [19] - The capital business grew in the low double digits, while instruments posted low single-digit growth [18] Market Data and Key Metrics Changes - International markets contributed to high single-digit growth in the CSF business, led by double-digit performance in China and Canada [18] - Demand indicators across global markets remain strong, despite challenges in specific segments [18] Company Strategy and Development Direction - The company is focused on four strategic imperatives: delivering best-in-class quality, driving supply chain reliability, accelerating growth, and igniting innovation [10] - A new operating model has been implemented to reduce complexity and improve efficiency, with a focus on quality and supply chain reliability [10] - The company aims to return key products to the market and recapture share while investing in innovation and portfolio prioritization [27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in long-term growth and value creation prospects, despite uncertainties related to recent tariff changes [13] - The company expects improved cash flow in 2026, with operating cash flow projected to exceed $200 million [32] - Management remains cautious about organic growth due to supply constraints but sees strong underlying demand across the portfolio [40] Other Important Information - The company is actively monitoring the impact of new tariffs following a Supreme Court ruling, which may affect future financial guidance [25] - The Braintree manufacturing facility is expected to be operational by the end of June 2026, supporting the return of SurgiMend to the market [11] Q&A Session Summary Question: Free cash flow generation and improvement - Management noted that negative free cash flow was driven by timing of collections and restructuring costs, but expects significant improvement in 2026 [31] Question: Tissue Technologies business and CMS changes - Management indicated that reimbursement changes are being monitored, with no expected negative impact on business due to pricing being within new reimbursement ranges [33] Question: Growth assumptions for CSS and Tissue Tech - Management expects low single-digit growth for CSS and low to mid single-digit growth for Tissue Tech in 2026, reflecting supply constraints rather than demand issues [40] Question: Status of MediHoney remediation efforts - Management confirmed that no revenues from MediHoney are accounted for in 2026 guidance, as remediation efforts continue [51] Question: Outlook for PriMatrix and DuraRepair - Early reception for PriMatrix and DuraRepair post-relaunch has been positive, with expectations for strong contributions in 2026 [48]

Core Insights - Integra LifeSciences reported quarterly earnings of $0.83 per share, exceeding the Zacks Consensus Estimate of $0.79 per share, but down from $0.97 per share a year ago, indicating an earnings surprise of +4.73% [1] - The company achieved revenues of $434.93 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 0.13%, although this is a decrease from $442.64 million in the same quarter last year [2] Earnings Performance - Over the last four quarters, Integra has surpassed consensus EPS estimates three times, indicating a positive trend in earnings performance [2] - The company had a previous earnings surprise of +25.58% when it reported $0.54 per share against an expectation of $0.43 per share [1] Stock Performance - Integra shares have declined approximately 6.7% since the beginning of the year, contrasting with the S&P 500's gain of 1.5%, suggesting underperformance relative to the broader market [3] Future Outlook - The company's earnings outlook is crucial for assessing future stock performance, with current consensus EPS estimates at $0.45 for the upcoming quarter and $2.31 for the current fiscal year [7] - The Zacks Rank for Integra is currently 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Instruments industry, to which Integra belongs, is currently in the top 30% of over 250 Zacks industries, suggesting a favorable industry outlook [8] - Another company in the same industry, Ekso Bionics, is expected to report a quarterly loss of $0.08 per share, reflecting a year-over-year change of +96.2%, with revenues projected at $5.65 million, up 11% from the previous year [9]

EARNINGS PRESENTATION Q4 2025 February 26, 2026 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties and reflect the Company's judgment as of the date of this release. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements. Some of these forward-looking statements may contain words like "will," "believe," "may ...

News Release Integra LifeSciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides 2026 Financial Guidance Princeton, New Jersey, February 26, 2026 - Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Full-Year 2025 "In the fourth quarter, we drove tangible operational progress while continuing to deliver for our customers and patients," said Mojdeh Poul, president ...